Stock listing
BOATS:SGP SpyGlass Pharma, Inc. Stock
US listing (BOATS) of SpyGlass Pharma, Inc. · home listing NASDAQ:SGP
Follow SpyGlass Pharma, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SGP
$30.43 USD +0.75 (+2.5%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SGP
- Day range
- $29.60 – $31.73 USDNov 20, 2026
- Volume
- 108,909 sharesNov 20, 2026
- Market cap
- $1.02B USDAt the close on Nov 20, 2026 · price × 33.46M shares outstanding
- Traded on an average day
- $3.32M USDMedian day 89,398 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SGP · Home | $30.43 USD | +0.75 (+2.5%) | 108,909 | $30.12 | $31.73 | $29.60 | $29.68 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SGP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $30.43 | +0.75 | +2.5% | $30.12 | $31.73 | $29.60 | 108,909 | |
| $29.68 | -1.755 | -5.6% | $31.44 | $31.95 | $29.10 | 95,000 | |
| $31.44 | -0.805 | -2.5% | $32.09 | $32.81 | $30.53 | 88,099 | |
| $32.24 | -0.64 | -1.9% | $32.48 | $32.81 | $29.16 | 246,130 | |
| $32.88 | -0.44 | -1.3% | $33.88 | $33.88 | $32.12 | 39,457 | |
| $33.32 | -1.65 | -4.7% | $35.68 | $35.68 | $33.15 | 54,414 | |
| $34.97 | +0.79 | +2.3% | $33.52 | $35.53 | $33.25 | 77,564 | |
| $34.18 | -4.19 | -10.9% | $38.00 | $38.00 | $33.71 | 94,126 | |
| $38.37 | +1.425 | +3.9% | $37.59 | $39.92 | $36.90 | 227,011 | |
| $36.95 | +2.865 | +8.4% | $34.50 | $37.12 | $33.93 | 109,374 | |
| $34.08 | -0.37 | -1.1% | $34.61 | $34.61 | $32.00 | 191,964 | |
| $34.45 | 0.00 | 0.0% | $35.07 | $35.75 | $33.51 | 201,017 | |
| $34.45 | +0.81 | +2.4% | $34.08 | $35.15 | $34.08 | 191,537 | |
| $33.64 | +1.40 | +4.3% | $32.71 | $33.96 | $31.60 | 94,805 | |
| $32.24 | -0.27 | -0.8% | $32.21 | $32.93 | $31.75 | 94,146 | |
| $32.51 | -0.35 | -1.1% | $33.12 | $33.84 | $31.68 | 125,359 | |
| $32.86 | +1.96 | +6.3% | $30.90 | $33.47 | $30.03 | 211,716 | |
| $30.90 | +0.99 | +3.3% | $30.01 | $31.06 | $29.41 | 69,335 | |
| $29.91 | +1.43 | +5.0% | $29.21 | $30.35 | $28.09 | 89,398 | |
| $28.48 | +0.26 | +0.9% | $28.00 | $28.70 | $26.68 | 70,600 | |
| $28.22 | +0.51 | +1.8% | $27.43 | $28.30 | $27.33 | 91,300 | |
| $27.71 | +1.55 | +5.9% | $26.52 | $27.73 | $26.04 | 86,100 | |
| $26.16 | +1.56 | +6.3% | $24.49 | $26.67 | $23.28 | 99,400 | |
| $24.60 | +0.60 | +2.5% | $24.36 | $25.15 | $24.34 | 69,800 | |
| $24.00 | -0.72 | -2.9% | $24.74 | $24.84 | $23.94 | 70,600 | |
| $24.72 | +1.03 | +4.3% | $23.67 | $24.93 | $23.50 | 47,100 | |
| $23.69 | -0.23 | -1.0% | $23.72 | $24.21 | $22.80 | 49,100 | |
| $23.92 | -0.94 | -3.8% | $24.53 | $24.85 | $23.89 | 63,900 | |
| $24.86 | -0.06 | -0.2% | $24.60 | $25.54 | $24.14 | 59,500 | |
| $24.92 | +0.30 | +1.2% | $25.03 | $25.79 | $24.63 | 68,300 | |
| $24.62 | +0.72 | +3.0% | $23.56 | $24.84 | $23.29 | 64,600 | |
| $23.90 | -0.88 | -3.6% | $24.46 | $24.76 | $23.62 | 69,500 | |
| $24.78 | -0.81 | -3.2% | $25.76 | $25.87 | $24.75 | 81,200 | |
| $25.59 | +0.67 | +2.7% | $24.78 | $25.71 | $24.60 | 133,100 | |
| $24.92 | -1.58 | -6.0% | $26.73 | $27.11 | $24.68 | 142,100 | |
| $26.50 | +0.50 | +1.9% | $26.30 | $26.81 | $25.34 | 101,100 | |
| $26.00 | +0.56 | +2.2% | $25.44 | $26.52 | $25.05 | 79,600 | |
| $25.44 | -0.54 | -2.1% | $25.84 | $26.25 | $24.40 | 67,900 | |
| $25.98 | -1.09 | -4.0% | $26.97 | $27.26 | $25.98 | 120,000 | |
| $27.07 | -0.58 | -2.1% | $27.51 | $27.92 | $26.85 | 96,400 | |
| $27.65 | -0.51 | -1.8% | $28.22 | $28.22 | $26.64 | 81,400 | |
| $28.16 | -0.53 | -1.8% | $28.99 | $29.28 | $27.76 | 149,300 | |
| $28.69 | +0.73 | +2.6% | $27.98 | $29.07 | $27.85 | 171,700 | |
| $27.96 | -1.12 | -3.9% | $29.40 | $29.96 | $27.29 | 174,300 | |
| $29.08 | -0.25 | -0.9% | $29.25 | $29.47 | $27.33 | 613,800 | |
| $29.33 | +0.73 | +2.6% | $29.12 | $29.75 | $28.62 | 235,600 | |
| $28.60 | -0.36 | -1.2% | $29.21 | $29.41 | $27.13 | 186,200 | |
| $28.96 | +0.30 | +1.0% | $28.57 | $29.04 | $27.00 | 131,700 | |
| $28.66 | +1.14 | +4.1% | $27.56 | $28.75 | $27.56 | 130,200 | |
| $27.52 | +0.21 | +0.8% | $27.68 | $28.40 | $27.29 | 169,500 | |
| $27.31 | -0.19 | -0.7% | $27.06 | $28.00 | $27.01 | 83,600 | |
| $27.50 | -1.42 | -4.9% | $28.77 | $29.17 | $27.09 | 78,400 | |
| $28.92 | -0.02 | -0.1% | $28.64 | $30.05 | $27.82 | 119,400 | |
| $28.94 | -0.05 | -0.2% | $28.81 | $29.18 | $28.03 | 75,100 | |
| $28.99 | +0.71 | +2.5% | $28.52 | $29.25 | $28.28 | 82,800 | |
| $28.28 | +1.42 | +5.3% | $26.95 | $28.74 | $26.95 | 113,500 | |
| $26.86 | +0.76 | +2.9% | $25.25 | $27.00 | $25.25 | 87,100 | |
| $26.10 | -0.32 | -1.2% | $26.42 | $26.66 | $25.53 | 64,800 | |
| $26.42 | -0.51 | -1.9% | $27.00 | $27.10 | $26.00 | 89,800 | |
| $26.93 | +0.29 | +1.1% | $26.65 | $27.39 | $26.35 | 66,000 | |
| $26.64 | +0.04 | +0.2% | $26.63 | $26.92 | $25.86 | 74,500 | |
| $26.60 | +0.34 | +1.3% | $26.45 | $26.93 | $26.16 | 60,332 | |
| $26.26 | -0.25 | -0.9% | $26.48 | $26.58 | $25.72 | 70,133 | |
| $26.51 | +0.28 | +1.1% | $26.55 | $27.44 | $26.27 | 52,300 | |
| $26.23 | -1.00 | -3.7% | $27.01 | $27.06 | $26.00 | 60,100 |
- Ticker
- BOATS:SGP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 11, 2026
SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 33 slides
Latest news
SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Nov 11, 2026
Closed $33.32 (-4.7%) on Nov 12, 2026
SpyGlass Pharma to Participate in Upcoming Investor Conferences
Nov 5, 2026
Closed $34.08 (-1.1%) on Nov 5, 2026
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
Oct 19, 2026
Closed $24.60 (+2.5%) on Oct 19, 2026
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
Oct 1, 2026
Closed $26.50 (+1.9%) on Oct 1, 2026
SpyGlass Pharma Celebrates Grand Opening of New Irvine Headquarters, Positioning Itself for First Product Launch and Custom R&D Space
Aug 28, 2026
Closed $26.42 (-1.9%) on Aug 28, 2026
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 6, 2026
Closed $25.31 (+2.3%) on Aug 7, 2026
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
Jun 15, 2026
Closed $18.94 (+2.7%) on Jun 15, 2026
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
Jun 2, 2026
Closed $18.36 (+0.2%) on Jun 2, 2026
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
May 18, 2026
Closed $22.24 (-4.2%) on May 18, 2026
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 14, 2026
Closed $23.21 (-4.4%) on May 15, 2026
SpyGlass Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 16 in all · newest Nov 11, 2026 · oldest 2026
- Decks
- 2 decks · latest August 2026
Where SpyGlass Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SGP · Home listing | NASDAQ | United States | USD |
| BOATS:SGP · This page | BOATS | United States | USD |
Valuation
Price/book 4.8× against a median of 4.0×: 6th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $809.5M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.8×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| SpyGlass Pharma, Inc. · NASDAQ:SGP | US$1.02B | US$809.5M | n/a | n/a | n/a | 4.8× | n/a | 0.0× | 1.01 |
| MedinCell SA · EURONEXT:MEDCL | US$1.05B | US$1.02B | n/a | 38.4× | n/a | 313× | −128.9% | 18.7× | n/a |
| Nektar Therapeutics · NASDAQ:NKTR | US$1.03B | US$492.8M | n/a | 9.4× | n/a | 1.2× | −339.7% | 0.1× | 1.28 |
| Mabwell (Shanghai) Bioscience Co., Ltd. Class A · SSE:688062 | US$1.02B | US$987.0M | n/a | 9.2× | n/a | 9.5× | −146.4% | 2.9× | n/a |
| Alto Neuroscience, Inc. · NYSE:ANRO | US$1.02B | US$711.7M | n/a | n/a | n/a | 3.4× | n/a | 0.1× | 1.65 |
| Inhibrx Biosciences, Inc. · NASDAQ:INBX | US$1.02B | US$1.09B | n/a | 546× | n/a | n/a | n/a | n/a | 1.89 |
| Duality Biotherapeutics, Inc. · HKEX:9606 | US$992.3M | US$608.2M | n/a | 4.8× | n/a | 4.6× | −170.8% | 0.3× | n/a |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.6M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.6M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Peptron, Inc. · KRX:087010 | US$979.6M | US$942.5M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| Median of the others | US$1.00B | US$931.4M | 10.4× | 9.4× | 95.7× | 4.0× | −137.6% | 0.2× | 1.65 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.
- Price target
- 46.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.77 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Patrick Mooney | Chief Executive Officer |
| Brian Aukshunas | Vice President, Finance |
| Jean-Frédéric Viret | Chief Financial Officer |
| Malik Y. Kahook | Co-founder, President, Chief Medical Officer, and Executive Chair of the Board |
| James Dennewill | Chief Operating Officer |
| Shannon Treviño | General Counsel |
| Anand Sundaram | Vice President, Head of Commercial |
| Laurie Mellott | Vice President, Clinical Operations |
| Mike Pinder | Vice President, Marketing |
| Nina Nguyen | Senior Vice President, Regulatory & Quality |
| Paul Yoo | Senior Vice President, Clinical Development |
| Rachel Gilette | Vice President, Human Resources |
| Chetan Pujara | Chief Research and Development Officer |
Board
| Director | Role |
|---|---|
| Malik Y. Kahook | Co-founder, President, Chief Medical Officer, and Executive Chair of the Board |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 11, 2026 · After close | −4.7% |
| Q2 2026 | Aug 6, 2026 · After close | +2.3% |
| Q1 2026 | May 14, 2026 · After close | −4.4% |
| Q4 2025 | Mar 27, 2026 | −7.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 33 slides | August 2026 |
| Interventional Glaucoma Consortium (IGC) Meeting 2025 | Conference | 14 slides | Nov 8, 2025 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$172.5M raised · US$16 a share · Jefferies +3 Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Citigroup (co-lead), Stifel (co-lead) | Feb 9, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Feb 5, 2026.
- Price
- US$16.00 a share
- Shares offered
- 9,375,000 shares of common stock
- Offering size
- US$150 million
- Underwriters' option
- Up to 1,406,250 more shares
- Listing
- SGP on the Nasdaq Global Select Market
- Underwriters
- Jefferies, Leerink Partners, Citigroup, Stifel · In the order on the cover
- Shares delivered
- On or about Feb 9, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 26, 2025 |
| Filed publicly | Jan 16, 2026 |
| Amended once | Jan 29, 2026 |
| Declared effective by the SEC | Jan 30, 2026 |
| Shares registered with an exchange | Feb 5, 2026 |
| Final prospectus, with the price | Feb 6, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 6, 2026 |
| CERT · Exchange's certificate of listing | Feb 5, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2026 |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 |
| CORRESP · Letter to the SEC | Jan 29, 2026 |
| CORRESP · Letter to the SEC | Jan 29, 2026 |
| CORRESP · Letter to the SEC | Jan 29, 2026 |
| S-1/A · Registration statement, amended | Jan 29, 2026 |
| UPLOAD · Letter from the SEC | Jan 27, 2026 |
| CORRESP · Letter to the SEC | Jan 16, 2026 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Jan 16, 2026 |
| UPLOAD · Letter from the SEC | Jan 13, 2026 |
| DRS/A · Draft registration statement, amended | Dec 10, 2025 |
| DRSLTR · Letter to the SEC with a draft | Dec 9, 2025 |
| UPLOAD · Letter from the SEC | Dec 1, 2025 |
| DRS · Draft registration statement | Sep 26, 2025 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 6, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of revenue | 612.0K | ||
| Gross profit | -612.0K | ||
| Research and development | 29.2M | 20.0M | 9.96M |
| Selling, general and administrative | 12.2M | 7.08M | 4.27M |
| Operating income | -41.4M | -27.1M | -14.2M |
| Depreciation and amortization | 612.0K | 271.0K | 122.7K |
| EBITDA | -40.8M | -26.8M | -14.1M |
| Income before tax | -39.9M | -29.2M | -13.3M |
| Income tax | 0 | 0 | |
| Net income | -39.9M | -29.2M | -13.3M |
| Earnings per share, basic | -17.98 | -16.31 | -0.42 |
| Earnings per share, diluted | -17.98 | -16.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | 96.4M | 16.3M | 15.8M |
| Short-term investments | 11.1M | 0 | 24.5M |
| Receivables | 431.0K | ||
| Current assets | 108.8M | 17.4M | 40.6M |
| Property, plant and equipment | 2.34M | 2.17M | |
| Total assets | 115.9M | 23.3M | 41.1M |
| Accounts payable | 2.70M | 1.98M | 639.2K |
| Current liabilities | 8.58M | 7.79M | 1.59M |
| Total debt | 1.58M | ||
| Total liabilities | 10.2M | 11.2M | 74.1M |
| Shareholders' equity | -98.8M | -60.5M | -33.0M |
| Shares outstanding | 2.20M | 2.20M | 31.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash from operations | -32.7M | -22.0M | -12.3M |
| Capital spending | -789.0K | -1.99M | -216.5K |
| Free cash flow | -33.5M | -24.0M | -12.5M |
| Cash from investing | -11.8M | 22.3M | |
| Cash from financing | 124.6M | 185.0K | 39.8M |
| Share buybacks | -1.45M | 0 | |
| Change in cash | 80.1M | 419.0K | 7.01M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 18, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
All 98 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 13, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 9, 2026 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| 424B4 · Prospectus | Feb 6, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 5, 2026 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Feb 5, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2026 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 29, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 29, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2026 | Other filings | SEC |
| S-1 · Registration statement | Jan 16, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 13, 2026 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Dec 9, 2025 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Dec 9, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 1, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Sep 26, 2025 | Offer document | SEC |
| D | Jun 5, 2025 | Other filings | SEC |
| D | Jul 11, 2023 | Other filings | SEC |
| D | Jan 5, 2021 | Other filings | SEC |
| D | Jun 5, 2019 | Other filings | SEC |
Cap table
Built by 6ix from SpyGlass Pharma, Inc.’s releases · as of Nov 2, 2026
- Common shares
- 33,461,450
- Fully diluted
- 33,461,450
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 33,461,450 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 33,461,450 |
| Sep 30, 2026 | 33,457,450 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Kolchinsky Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Wave Life Sciences Ltd. (Director · Since at least Aug 14, 2015); Black Diamond Therapeutics, Inc. (Director · Jul 5, 2023 – Jul 5, 2023 · Past); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Research Alliance Corp II (Chief Executive Officer, Director · Mar 17, 2021 – Mar 17, 2021 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Solid Biosciences Inc. (Director · Dec 10, 2020 – Jan 11, 2024 · Past); POINT Biopharma Global Inc (Chief Executive Officer, Director · Jul 7, 2020 – Jun 29, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 8, 2022 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 3, 2022 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Kala Bio, Inc. (Director · Oct 3, 2018 – Mar 13, 2020 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – Jun 19, 2018 · Past); KalVista Pharmaceuticals, Inc. (Director · Oct 12, 2017 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Jun 20, 2017 – Apr 2, 2020 · Past); Dicerna Pharmaceuticals Inc (Director · Jan 29, 2014 – Nov 27, 2019 · Past) | Director · Since at least Feb 5, 2026 |
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Feb 5, 2026 |
| Ali Behbahani Other companies: NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Feb 5, 2026 |
| Habib Joseph Dable Other companies: Tyra Biosciences, Inc. (Board Member · Since at least Apr 16, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Non-Executive Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Tempest Therapeutics, Inc. (Director · Dec 7, 2018 – Jun 22, 2020 · Past); Acceleron Pharma Inc (CEO and President, Director · Dec 1, 2016 – Nov 19, 2021 · Past) | Director · Since at least Feb 5, 2026 |
| Geoff Pardo Other companies: Shoulder Innovations, Inc. (Director · Since at least Jul 30, 2025); CVRx, Inc. (Director · Jun 29, 2021 – Jul 2, 2021 · Past); Eargo, Inc. (Director · Oct 15, 2020 – Apr 30, 2021 · Past); Inari Medical Inc (Director · May 21, 2020 – May 27, 2020 · Past); Vapotherm Inc (Director · Nov 13, 2018 – Sep 1, 2020 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Dec 6, 2018 · Past) | Director · Since at least Feb 5, 2026 |
| Elizabeth G. O’Farrell Other companies: LENSAR, Inc. (Director · Since at least Feb 1, 2021); Geron Corporation (Director · Since at least Mar 26, 2019); Inhibikase Therapeutics, Inc. (Director · Dec 22, 2020 – Jun 24, 2022 · Past); PDL BioPharma Inc (Director · Jun 22, 2018 – Nov 23, 2020 · Past) | Director · Since at least Feb 5, 2026 |
| Michael Dybbs Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past) | Director · Since at least Feb 5, 2026 |
| Jean-Frédéric Viret Other companies: NGM Biopharmaceuticals Inc (Chief Financial Officer · Nov 3, 2023 – Mar 26, 2024 · Past); Coherus Oncology, Inc. (Chief Financial Officer · Nov 6, 2014 – Feb 1, 2021 · Past); Anesiva Inc (VP and Chief Financial Officer · Mar 1, 2008 – Dec 3, 2008 · Past) | Chief Financial Officer · Since at least Feb 5, 2026 |
| Kirk Nielsen Other companies: CVRx, Inc. (Director · Since at least Jun 29, 2021); Inari Medical Inc (Director · May 21, 2020 – May 27, 2023 · Past) | Director · Since at least Feb 5, 2026 |
| Zach Scheiner Other companies: LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Nkarta, Inc. (Member of Board of Directors · Since at least Jul 9, 2020) | Director · Since at least Feb 5, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Anand Sundaram | Vice President, Head of Commercial · Since at least Nov 4, 2026 |
| Bilal Arshad Khan | Director · Since at least Feb 5, 2026 |
| Brian Aukshunas | Vice President, Finance · Since at least Nov 4, 2026 |
| Chetan Pujara | Chief R&D Officer · Since at least Feb 5, 2026 |
| James Dennewill | Chief Operating Officer · Since at least Aug 28, 2026 |
| James Robert Dennewill Jr | Chief Operating Officer · Since at least Feb 5, 2026 |
| Laurie Mellott | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Malik Y. Kahook | Co-founder, President, Chief Medical Officer, and Executive Chair of the Board · Since at least Feb 5, 2026 |
| Mike Pinder | Vice President, Marketing · Since Jun 2, 2026 · Appointed, no departure found |
| Mike Pinder | Vice President, Marketing · Since at least Jun 2, 2026 |
| Nina Nguyen | Senior Vice President, Regulatory & Quality · Since at least Nov 4, 2026 |
| Patrick Mooney | Chief Executive Officer, Director · Since at least Feb 5, 2026 |
| Paul Yoo | Senior Vice President, Clinical Development · Since at least Oct 19, 2026 |
| Rachel Gilette | Vice President, Human Resources · Since at least Nov 4, 2026 |
| Shannon Treviño | General Counsel · Since at least Jun 15, 2026 |
Log in to ask 6ix AI your own questions about SpyGlass Pharma, Inc.